Introduction
============

In 2016, the European Centre for Disease Prevention and Control (ECDC) estimated that the burden of six main types of healthcare-associated infection (healthcare-associated pneumonia, urinary tract infection, surgical site infection, *Clostridium difficile* infection, neonatal sepsis and primary bloodstream infection)) expressed in disability-adjusted life years (DALYs) in the European Union and European Economic Area (EU/EEA) was higher than the combined burden of 31 other infectious diseases under surveillance by ECDC \[[@r1],[@r2]\]. The estimated number of healthcare-associated infections (HAI) used in the study was based on the data of the first ECDC point prevalence survey (PPS) of HAI and antimicrobial use in acute care hospitals (ACH) from 2011 to 2012 \[[@r3]\] and did not take into account HAI occurring in other healthcare facilities. In particular, ECDC had previously estimated that the number of residents with an HAI on any given day in European long-term care facilities (LTCF) was of the same order of magnitude as the number of patients with an HAI on any given day in ACH \[[@r4]-[@r6]\].

In the period from 2016 to 2017, ECDC organised two PPS of HAI and antimicrobial use: the second PPS in ACH and the third PPS in LTCF in the EU/EEA. The objective of the current study was to report on the HAI and antimicrobial resistance results of both surveys and to estimate the combined total number of HAI on any given day and the number of HAI per year from 2016 to 2017 in the EU/EEA.

Methods
=======

Participation of countries
--------------------------

All EU/EEA countries and EU candidate and potential candidate countries were invited to organise a national PPS in ACH and LCTF in their country in any of four periods (April to June or September to November of 2016 or 2017). For reasons of feasibility at national level, the PPS in ACH and LCTF could be organised during different periods. Data were collected according to two specific standardised ECDC protocols \[[@r7],[@r8]\]. All countries used the ECDC protocols and included all HAI types except for one country (Norway) for ACH and four countries (France, the Netherlands, Norway and Sweden) for LCTF. Norway used national protocols with the same case definitions as in the ECDC protocols, but provided fewer details and did not require the inclusion of all types of HAI. LTCF data from France and the Netherlands were also collected using national protocols not including all types of HAI. LTCF protocols in France, the Netherlands and Norway all included urinary tract infections, lower respiratory tract infections and skin infections, in addition other HAI types varying by country. Surveys in separate healthcare administrations in the United Kingdom (UK), i.e. England, Northern Ireland, Scotland and Wales, were organised independently and results were reported separately.

Selection of participating facilities and patients
--------------------------------------------------

It was recommended that countries selected the participating ACH and LCTF by systematic random sampling from national lists ranked by type and size to ensure optimal country representativeness. For each country, the required sample size was calculated for an estimated prevalence of 6% for ACH and 4% for LCTF, based on the results of the previous PPS \[[@r3],[@r6]\], with an absolute precision of 1%. Representativeness was categorised as optimal, good, poor or very poor, depending on the sampling method of the facilities, the number of included patients/residents and the number of included facilities \[[@r7],[@r8]\]. For example, 'optimal representativeness' meant that the country performed systematic sampling of at least 25 healthcare facilities or included at least 75% of all facilities or beds at national level, and achieved the recommended sample size.

For ACH, the protocol recommended that data from a single ward should be collected on one single day and that the time frame for data collection for all wards of a single hospital would not exceed 3 weeks. For LCTF, it was recommended to collect data on a single day, except for larger LCTF.

We included all patients/residents present on the hospital ward or LTCF at 8:00 on the day of the PPS and still present at the time of day when the PPS was performed. In addition, LTCF residents needed to be full-time residents (i.e. living 24 hours a day in the LTCF). Patients/residents who were temporarily absent from their room, e.g. for diagnostic procedures, had to be included.

Case definitions
----------------

Case definitions for HAI differed for ACH and for LCTF, reflecting differences in access to diagnostic methods between the two settings, as well as the specific signs and symptoms of infection in elderly LTCF residents \[[@r7],[@r8]\]. For both PPS, an HAI was defined as active on the day of the PPS when signs and symptoms were present on the date of the PPS, or when signs and symptoms were no longer present but the patient/resident was still receiving treatment for that infection on the date of the PPS. HAI present on admission were included in both protocols. In the LTCF protocol, HAI associated with a stay in any other healthcare facility -- another LTCF or a hospital --­ were included. In the ACH protocol, however, only HAI imported from other ACH were included, excluding HAI present on admission associated with a previous LTCF stay. LTCF data in France and Sweden did not include HAI imported from other healthcare facilities.

Data analysis
-------------

Data were analysed with Stata, version 14.1 (StataCorp, Texas, United States). The prevalence of HAI was expressed as the percentage of patients/residents with at least one HAI on the day of the PPS. To account for clustering within ACH or LCTF, 95% confidence intervals (CI) were calculated using the svy proportion command in Stata. Overall weighted prevalence percentages were calculated by applying the country-specific prevalence on the number of occupied beds in each country and summing up the total number of patients with at least one HAI for EU/EEA countries. National denominator data were obtained by questionnaire from national survey coordinators, from Eurostat data if national denominator data were not submitted \[[@r9]-[@r11]\] or from the previous PPS if Eurostat data were missing or incomplete \[[@r3],[@r4],[@r6]\]. To estimate the total number of HAI or patients with at least one HAI for the whole EU/EEA, the average results from participating EU/EEA countries were applied to the national denominator data from non-participating EU/EEA countries. For data collected using national protocols which did not include all types of HAI, imputation of non-included types of HAI was done based on EU/EEA averages to make prevalence percentages comparable. In ACH, imputation resulted in adding 7.3% (36/495) of patients with HAI in Norway. In LCTF, imputation resulted in adding 5.8% (12/206) of residents with HAI in France, 6.9% (11/160) in the Netherlands and 7.6% (9/119) in Norway, or 0.8% (32/3,780) overall. As these imputations were done for the aggregated national results, correction of CI for clustering within LCTF could not be applied for these countries and binomial exact CI were used instead.

Antimicrobial resistance
------------------------

Antimicrobial resistance (AMR) in HAI was evaluated using two indicators: a composite index of AMR and the percentage of carbapenem-resistant Enterobacteriaceae. The composite index of AMR was calculated as the percentage of resistant isolates for the 'first level' AMR markers in the PPS protocols divided by the sum of the isolates for which results from antimicrobial susceptibility testing (AST) were reported. These first level markers were *Staphylococcus aureus* resistant to meticillin (MRSA), *Enterococcus faecium* and *Enterococcus faecalis* resistant to vancomycin, Enterobacteriaceae resistant to third-generation cephalosporins, and *Pseudomonas aeruginosa* and *Acinetobacter baumannii* resistant to carbapenems. The percentage of resistant isolates was not calculated when less than 10 isolates with known AST results were reported. The composite index of AMR at country level was validated by examining the correlation with the composite AMR index calculated from EARS-Net data from 2016, including all components of the index except AST results for Enterobacteriaceae other than *Escherichia coli* and *Klebsiella pneumoniae* because they are not included in EARS-Net \[[@r12],[@r13]\]. Correlations were analysed using the Spearman correlation coefficient rho and the R-squared (R^2^) and regression coefficient from linear regression.

Prevalence to incidence conversion
----------------------------------

Estimates of the total number of HAI and patients acquiring at least one HAI per year in ACH were based on prevalence to incidence conversion using the Rhame and Sudderth formula \[[@r14]\]. Details of the method are reported in the ECDC PPS report for 2011 and 2012 \[[@r3]\]. In addition, sensitivity analyses of the conversion were carried out using a method developed by Willrich et al. (personal communication: Niklas Willrich, 24 May 2018), in which the estimates of the length of stay were based on a Grenander estimator for discrete monotonously decreasing distributions \[[@r15]\].

In LCTF, only the number of HAI could be estimated. As LTCF usually are permanent residences, HAI do not prolong the length of stay of a resident as they do in ACH. Therefore, the incidence of HAI in LCTF per year was estimated by multiplying the prevalence by 365 days and dividing it by the duration of infection (in days), with a correction for an average occupancy of LTCF beds of 95%, calculated from institutional denominator data. The duration of infection was estimated, by type of HAI, from the date of onset to the date of the PPS, using the median duration of HAI until the day of the PPS multiplied by 2.

Validation studies
------------------

It was strongly recommended that all participating EU/EEA countries perform validation studies of their national PPSs. For the PPS in ACH, ECDC also offered financial support to national institutions coordinating PPS so that they could organise validation studies with a minimum requirement to re-examine 250 patient charts in five ACH. For both the PPS in ACH and that in LCTF, the objective was to estimate representative validity parameters at the EU/EEA level rather than at country level (\[[@r16]\]; ACH validation protocol available from the authors on request). Validation studies were performed by national validation teams composed of members of the national coordination teams, using the ECDC HAI case definitions as gold standard. Validation results were calculated for each country, by matching patients included in the validation sample with their corresponding data collected in the primary PPS. The percentage of false positives (FP) and false negatives (FN) was calculated from the matched analysis and applied to the total national database to calculate the sensitivity and specificity for each country, as several countries selected high prevalence wards for validation to improve precision as recommended by the validation study protocol. For correction of the EU/EEA prevalence of HAI, the EU/EEA mean FN and FP were applied to the total number of patients. The validation-corrected HAI prevalence was converted using the Rhame and Sudderth formula to estimate the corrected HAI incidence and total number of patients in ACH with at least one HAI per year in the period 2016 to 2017.

To calculate CI around EU/EEA estimates, the number of patients with at least one HAI obtained from the lower and upper limits of the country-specific 95% CIs were summed up and divided by the total number of occupied beds (for prevalence) or the total number of discharges (for estimated incidence) in the EU/EEA. These 'cumulative 95% CI' (95% cCI) therefore reflect a larger, more conservative uncertainty than would be obtained by calculating 95% CI on the EU/EEA totals, which is in accordance with the limitations of the prevalence measurement and the uncertainty inherent to the conversion of prevalence to incidence.

Results
=======

Point prevalence survey in acute care hospitals
-----------------------------------------------

### Participation

In total, 1,735 hospitals from 28 EU/EEA countries and one EU candidate country (Serbia) participated in the second PPS of HAI and antimicrobial use in European ACH in the period 2016 to 2017. Counting UK administrations separately, the country representativeness of the sample was optimal in 20 countries, good in 10, and poor in two countries. After adjustment for over-representation of countries contributing more than 20,000 patients to the PPS, 325,737 patients from 1,275 ACH remained in the final sample. Aggregated results were only reported for the EU/EEA, corresponding to 310,755 patients from 1,209 ACH. The distribution of the type of ACH and the percentage of patients requiring intensive care by country is shown in [Table 1](#t1){ref-type="table"}.

###### Key characteristics of healthcare facilities, patients and residents included in the point prevalence survey (PPS) samples, PPS in acute care hospitals (n = 1,275) and long-term care facilities (n = 2,242), 30 EU/EEA countries, Serbia and the former Yugoslav Republic of Macedonia, 2016--2017

  Country                                 ACH     LTCF                                                                                                                  
  --------------------------------------- ------- ------- ------- ------- ------- ------- ------ ------ -------- ------- ------- ------- ------- ------- ------- ------ ------
  Austria                                 162     49      25      11      2       11      0      4.0    817      14      0       7       5       2       35.8    10.8   1.0
  Belgium                                 197     43      27      9       7       0       0      4.9    1,559    86      79      0       0       7       56.5    3.1    0.9
  Bulgaria                                241     12      1       4       7       0       0      6.9    33       NP      NA      NA      NA      NA      NA      NA     NA
  Croatia                                 32      34      6       15      9       4       0      6.0    325      8       0       0       8       0       40.9    3.1    1.1
  Cyprus                                  83      8       2       4       2       0       0      9.6    90       13      7       0       4       2       54.8    8.0    4.8
  Czech Republic                          144     45      2       30      11      2       0      8.1    73       11      0       4       5       2       NA      NA     NA
  Denmark                                 52      NP      NA      NA      NA      NA      NA     NA     827      95      0       0       95      0       51.8    9.0    1.7
  Estonia                                 27      23      10      7       1       4       1      3.3    59       NP      NA      NA      NA      NA      NA      NA     NA
  Finland                                 59      51      18      16      14      2       1      3.8    1,928    157     148     0       1       8       51.4    4.2    0.6
  France                                  1,237   50      32      10      6       2       0      3.8    9,744    91      91      0       0       0       61.6    1.6    0.8
  Germany                                 1,857   49      25      7       4       13      0      5.0    10,389   84      55      15      12      2       49.6    8.6    1.3
  Greece                                  123     42      1       23      16      2       0      7.6    263      13      0       0       13      0       48.8    12.1   0.7
  Hungary                                 94      38      14      10      6       7       1      2.8    1,177    111     65      9       1       36      25.3    1.9    0.7
  Iceland                                 8       2       0       1       1       0       0      5.2    43       NP      NA      NA      NA      NA      NA      NA     NA
  Ireland                                 60      60      9       17      7       27      0      3.0    578      185     75      0       34      76      47.7    7.0    1.5
  Italy                                   1,134   56      13      14      25      4       0      6.0    3219     215     61      85      50      19      54.0    12.1   1.3
  Latvia                                  24      14      0       9       3       2       0      3.5    82       NP      NA      NA      NA      NA      NA      NA     NA
  Lithuania                               64      62      25      26      8       3       0      2.8    154      26      0       0       26      0       12.4    0.8    0.3
  Luxembourg                              12      12      2       5       1       3       1      5.9    62       16      15      1       0       0       58.4    5.3    1.5
  Malta                                   4       4       1       1       1       1       0      4.8    41       11      0       8       3       0       51.1    5.0    0.6
  The Netherlands                         79      19      10      8       1       0       0      6.0    700      57      0       0       57      0       43.0    6.6    3.5
  Norway                                  53      43      11      9       4       0       19     6.3    907      62      62      0       0       0       NA      10.0   3.4
  Poland                                  936     80      22      20      23      15      0      3.8    373      25      12      12      0       1       30.5    19.4   0.9
  Portugal                                225     93      24      40      18      9       2      4.2    360      268     0       0       132     136     29.6    15.1   0.9
  Romania                                 311     40      16      10      3       11      0      6.4    628      NP      NA      NA      NA      NA      NA      NA     NA
  Slovakia                                107     50      20      11      7       12      0      5.2    677      69      27      0       32      10      28.3    3.1    1.1
  Slovenia                                21      20      0       11      3       6       0      5.8    90       NP      NA      NA      NA      NA      NA      NA     NA
  Spain                                   576     96      17      39      32      5       3      5.0    5,387    46      0       0       46      0       48.1    5.1    5.1
  Sweden                                  144     NP      NA      NA      NA      NA      NA     NA     2,300    417     285     0       0       132     57.9    9.9    2.1
  UK--England                             158     32      0       19      10      3       0      3.4    17,473   NP      NA      NA      NA      NA      NA      NA     NA
  UK--Northern Ireland                    16      16      6       4       2       4       0      3.2    445      70      0       15      55      0       44.8    5.0    0.6
  UK--Scotland                            46      45      12      14      7       12      0      2.8    873      52      34      17      1       0       43.9    8.5    0.3
  UK--Wales                               21      21      6       10      4       1       0      3.7    795      30      9       7       12      2       49.7    7.8    1.7
  EU/EEA                                  8,307   1,209   357     414     245     165     28     4.6%   62,471   2,232   1025    180     592     435     45.6%   6.7%   1.5%
  EU/EEA (n, %, mean of countries)        252     100%    29.5%   34.2%   20.3%   13.6%   2.3%   4.9%   1,893    100%    45.9%   12.3%   22.3%   19.5%   44.8%   7.3%   1.5%
  Former Yugoslav Republic of Macedonia   ND      NP      NA      NA      NA      NA      NA     NA     21       4       3       0       1       0       15.3    8.8    0.7
  Serbia                                  66      66      1       45      14      6       0      6.5    90       6       0       0       6       0       28.1    6.1    0.6

ACH: acute care hospital; EU/EEA: European Union/European Economic Area; LTCF: long-term care facility; NA: not applicable; ND: no data collected in national protocol; NP: did not participate; PPS: point prevalence survey; UK: United Kingdom.

Country data representativeness was poor in Bulgaria and the Netherlands for the PPS in ACH and poor in Austria, Croatia, Cyprus, Greece, Luxembourg, Malta and Poland for the PPS in LTCF. The Czech Republic only submitted data on institutional indicators.

### Prevalence and estimated incidence of healthcare-associated infections

A total of 19,626 HAI were reported in 18,287 patients with HAI (1.07 HAI per infected patient). The prevalence of patients with at least one HAI in the EU/EEA sample was 5.9% (country range: 2.9--10.0%; [Table 2](#t2){ref-type="table"}). The prevalence varied between 4.4% (2,177/49,381 patients) in primary care hospitals (n = 333) to 7.1% (7,591/104,562 patients) in tertiary care hospitals (n = 222) and was highest in patients admitted to intensive care units, where 19.2% (2,751/14,258) patients had at least one HAI compared with 5.2% (15,536/296,397) on average for all other specialties combined (Supplement).

###### Prevalence and estimated incidence of healthcare-associated infections in European acute care hospitals, 28 EU/EEA countries and Serbia, 2016--2017 (n = 325,737 patients)

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Country                                   Patients in PPS sample   Patients with at least one HAI in PPS sample\   Validation-corrected\   Occupied beds in the country\   Patients with at least one HAI on a given day, estimated   Hospital discharges annually in the country   HAI incidence, estimated   Patients with at least one HAI, annually, estimated                                                             
                                                                     (HAI prevalence)^a^                             HAI\                    (average per day)                                                                                                                                                                                                                                                                   
                                                                                                                     prevalence^b^                                                                                                                                                                                                                                                                                               
  ----------------------------------------- ------------------------ ----------------------------------------------- ----------------------- ------------------------------- ---------------------------------------------------------- --------------------------------------------- -------------------------- ----------------------------------------------------- ---------------- --------- -------------- --------------- --------------------------
  Austria                                   13,461                   541                                             4.0                     3.4--4.7                        NR                                                         36,351                                        1,461                      1,243--1,716                                          2,707,753        2.3       1.5--3.3       62,306          40,978--89,762

  Belgium                                   11,800                   856                                             7.3                     6.4--8.3                        NR                                                         37,651                                        2,731                      2,397--3,109                                          1,858,726        5.4       3.7--7.6       101,110         68,186--141,713

  Bulgaria ^c^                              2,200                    76                                              3.5                     1.7--6.8                        NR                                                         25,324                                        875                        434--1,733                                            1,632,089        1.8       0.9--3.8       29,572          13,909--61,597

  Croatia                                   10,466                   551                                             5.3                     4.5--6.2                        NR                                                         11,047                                        581                        495--683                                              667,849          4.1       2.8--5.6       27,129          18,937--37,561

  Cyprus                                    1,036                    85                                              8.2                     5.4--12.4                       ND                                                         1,437                                         118                        77--178                                               166,295          4.8       2.5--8.7       8,010           4,158--14,541

  Czech Republic                            15,117                   1,015                                           6.7                     5.9--7.6                        NR                                                         40,691                                        2,732                      2,413--3,090                                          2,260,239        5.4       3.9--7.3       122,313         87,039--165,208

  Estonia                                   4,220                    178                                             4.2                     2.4--7.3                        NR                                                         4,582                                         193                        111--332                                              222,363          3.3       1.6--6.6       7,393           3,558--14,761

  Finland                                   9,079                    803                                             8.8                     7.5--10.4                       NR                                                         15,894                                        1,406                      1,187--1,660                                          915,892          5.1       3.3--7.5       46,735          30,053--68,350

  France                                    16,522                   965                                             5.8                     4.9--7.0                        NR                                                         159,810                                       9,334                      7,823--11,116                                         11,330, 996      4.1       2.7--5.9       467,961         311,830--671,498

  Germany                                   11,324                   409                                             3.6                     2.8--4.7                        NR                                                         400,132                                       14,452                     11,087--18,789                                        19,480,504       3.1       1.9--4.8       604,495         373,766--938,383

  Greece                                    9,401                    938                                             10.0                    8.5--11.6                       NR                                                         18,252                                        1,821                      1,559--2,121                                          1,562,761        4.3       3.1--5.7       66,487          48,386--89,068

  Hungary                                   20,588                   818                                             4.0                     3.3--4.8                        NR                                                         46,134                                        1,833                      1,516--2,212                                          2,226,485        3.5       2.1--5.4       78,095          46,906--120,082

  Iceland                                   633                      40                                              6.3                     0.8--36.8                       5.7                                                        642                                           41                         5--237                                                39,198           6.7       0.6--48.6      2,609           239--19,038

  Ireland                                   10,333                   633                                             6.1                     5.0--7.5                        NR                                                         10,932                                        670                        546--820                                              705,000          4.2       2.7--6.3       29,671          18,846--44,323

  Italy                                     14,773                   1,186                                           8.0                     6.8--9.5                        NR                                                         167,619                                       13,457                     11,362--15,899                                        8,930,979        6.0       4.2--8.3       534,709         373,705--740,544

  Latvia                                    3,807                    140                                             3.7                     2.6--5.2                        4.9                                                        5,127                                         189                        132--268                                              300,575          2.5       1.4--4.1       7,447           4,322--12,399

  Lithuania                                 12,415                   359                                             2.9                     2.1--4.0                        3.2                                                        14,613                                        423                        301--590                                              705,224          2.6       1.3--4.6       18,046          9,322--32,167

  Luxembourg                                2,018                    103                                             5.1                     4.0--6.5                        8.5                                                        1,860                                         95                         75--120                                               74,782           3.4       2.1--5.3       2,569           1,560--3,995

  Malta                                     961                      60                                              6.2                     5.2--7.4                        7.9                                                        972                                           61                         51--72                                                72,909           2.6       1.9--3.4       1,877           1,380--2,507

  The Netherlands^c^                        4,441                    170                                             3.8                     3.4--4.3                        NR                                                         24,167                                        925                        826--1,036                                            1,700,000        2.3       1.6--3.2       39,585          27,525--54,115

  Norway^d^                                 9,628                    495                                             5.1                     4.1--6.4                        ND                                                         10,505                                        540                        430--677                                              776,203          2.4       1.5--3.6       18,767          11,873--28,340

  Poland                                    21,712                   1,249                                           5.8                     4.8--6.9                        4.7                                                        120,492                                       6,931                      5,764--8,317                                          8,254,611        3.5       2.3--5.0       289,602         193,881--415,274

  Portugal                                  16,982                   1,544                                           9.1                     8.1--10.2                       7.8                                                        27,907                                        2,537                      2,236--2,841                                          1,128,245        5.9       4.4--7.8       66,860          49,568--87,500

  Romania                                   11,443                   417                                             3.6                     2.8--4.7                        5.9                                                        57,091                                        2,080                      1,610--2,682                                          3,674,275        2.6       1.7--4.0       97,257          62,340--146,893

  Slovakia                                  9,145                    370                                             4.1                     3.1--5.3                        NR                                                         20,279                                        820                        630--1,066                                            1,005,003        3.1       2.1--4.6       31,519          20,848--46,607

  Slovenia                                  5,720                    373                                             6.5                     5.8--7.3                        ND                                                         5,581                                         363                        322--409                                              380,077          4.4       3.3--5.6       16,635          12,630--21,441

  Spain                                     19,546                   1,516                                           7.8                     7.1--8.5                        NR                                                         84,908                                        6,586                      5,983--7,243                                          5,247,215        4.9       3.6--6.4       255,169         186,398--335,644

  UK--England                               20,148                   1,297                                           6.4                     5.4--7.6                        NR                                                         96,774                                        6,230                      5,264--7,358                                          9,450,142        2.2       1.4--3.2       205,722         130,191--303,990

  UK--Northern Ireland                      3,813                    234                                             6.1                     4.8--7.9                        5.8                                                        4,965                                         305                        236--392                                              302,008          3.5       1.8--5.9       10,527          5,559--17,841

  UK--Scotland                              11,623                   504                                             4.3                     3.5--5.3                        NR                                                         11,448                                        496                        406--606                                              1,156,473        2.2       1.5--3.2       25,539          16,992--36,977

  UK--Wales                                 6,400                    362                                             5.7                     4.7--6.7                        6.0                                                        6,715                                         380                        318--453                                              827,634          2.2       1.3--3.3       17,880          10,595--27,545

  **Participating EU/EEA countries^a,e^**   **310,755**              **18,287**                                      **5.5**                 **4.5--6.7**                    **6.5**                                                    **1,469,903**                                 **80,665**                 **66,864--97,824**                                    **89,762,505**   **3.7**   **2.4--5.3**   **3,293,595**   **2,185,484--4,789,661**

  Serbia                                    14,982                   650                                             4.3                     3.5--5.4                        NR                                                         18,920                                        821                        656--1,024                                            988,383          3.3       2.3--4.6       32,337          22,714--45

  EU/EEA, corrected**^e,f^**                NA                       NA                                              5.5                     4.5--6.7                        6.5                                                        1,503,881                                     82,713                     67,674--99,256                                        91,885,503       3.7       2.4--5.3       3,372,146       2,220,554--4,854,535

  **EU/EEA, corrected after validation**    NA                       NA                                              **6.5**                 **5.4--7.8**                    NA                                                         1,503,881                                     **98,166**                 **81,022--117,484**                                   91,885,503       **4.1**   **3.4--4.9**   **3,758,014**   **3,122,024--4,509,617**
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CI: confidence interval; EU/EEA: European Union/European Economic Area; HAI: healthcare-associated infection; NA: not applicable; ND: validation study not done NR: validation study not representative of country PPS sample; PPS: point prevalence survey; UK: United Kingdom.

^a^ Country-weighted HAI prevalence for the EU/EEA = estimated number of patients with at least one HAI a single day / occupied beds.

^b^ Validation-corrected prevalence of patients with at least one HAI: only given for countries that reached national representativeness for their national validation study (at least 75% of recommended sample size of 750 validated patients and/or validation of at least 75% of included hospitals).

^c^ Poor country representativeness in Bulgaria and the Netherlands.

^d^ Norway used a national PPS protocol requiring imputation of non-included types of HAI for 24 hospitals.

^e^ Cumulative 95% CI for the EU/EEA. Cumulative sums are rounded and may differ from the sum of the individual rounded country estimates.

^f^ Corrected for non-participating EU countries with estimation for Denmark and Sweden combined.

When extrapolated to the average daily number of occupied beds per country, the weighted HAI prevalence was 5.5% (95% cCI: 4.5--6.6%). The weighted annual incidence of patients acquiring at least one HAI per year in the period 2016 to 2017, estimated using prevalence to incidence conversion, was 3.7 (95% cCI: 2.4--5.3) patients per 100 admissions. National PPS validation studies were carried out by 28 countries (UK administrations counted separately) in a total of 236 ACH in the EU/EEA. National validation teams re-examined 12,228 patient charts independently from the primary PPS surveyors. These studies showed that on average, 2.3% (country range: 0.3--5.6%) of patients who were reported as not having a HAI actually had an HAI (false negatives) while one in five (mean: 20.3%, country range: 0--46.2%) patients reported as having an HAI did not have an HAI (false positives), resulting in a mean sensitivity of HAI detection of 69.4% (country range: 40.1--94.4%) and a mean specificity of 98.8% (country range: 96.1--100%). When correcting for these results, the adjusted prevalence of patients with at least one HAI was estimated at 6.5% (95% cCI: 5.4--7.8%). Using the Rhame and Sudderth formula to convert the latter percentage, the corrected annual incidence was estimated at 4.1 (95% cCI: 3.4--4.9) patients per 100 admissions. Applying the EU/EEA averages to denominator data from non-participating EU/EEA countries (Denmark and Sweden), this resulted in an estimated total of 98,166 (95% cCI: 81,022--117,484) patients with at least one HAI on any given day and 3,758,014 (95% cCI: 3,122,024--4,509,617) patients with at least one HAI per year in the period 2016 to 2017 in ACH in the EU/EEA.

### Types of HAI and isolated microorganisms

The most frequently reported types of HAI were respiratory tract infections (21.4% pneumonia and 4.3% other lower respiratory tract infections), urinary tract infections (18.9%), surgical site infections (18.4%), bloodstream infections (10.8%) and gastro-intestinal infections (8.9%), with *C. difficile* infections accounting for 44.6% of the latter or 4.9% of all HAI. Twenty-three per cent of HAI were present on admission. One third of HAI on admission were surgical site infections. Country-weighted prevalence percentages and estimated numbers of HAI per year are shown in [Table 3](#t3){ref-type="table"}. After correction for non-participating countries and validation, a total of 4.5 million (95% cCI: 2.6--7.6 million) HAI were estimated to occur per year in the period 2016 to 2017 in ACH in the EU/EEA.

###### Country-weighted prevalence and estimated incidence of healthcare-associated infections (HAI) by type of HAI in European acute care hospitals (n = 19,626) and long-term care facilities (n = 3,858), 30 EU/EEA countries, 2016--2017

  Type of HAI                                                Acute care hospitals   Long-term care facilities                                                                                                                                                                                      
  ---------------------------------------------------------- ---------------------- --------------------------- ------ ------------- ------------- --------------------- --------------- -------------------------- ------- ------ ------ ------------ --------- ----------------- --------------- --------------------------
  Respiratory tract infection                                                                                                                                                                                                                                                                      
  Pneumonia                                                  4,200                  21.4                        1.26   0.96--1.68    18,935        14,398--25,265        862,084         567,728--1 283,203         143     3.7    0.15   0.06--0.32   4,948     1,946--10 658     112,868         44,390--243,134
  Other lower respiratory tract infection^b^                 838                    4.3                         0.24   0.15--0.41    3,568         2,208--6,192          183,232         91,731--376,990            847     22.0   0.88   0.59--1.14   29,010    19,412--37,826    1,058,853       708,542--1 380,653
  Common cold/influenza                                      NI                     NA                          NA     NA            NA            NA                    NA              NA                         290     7.5    0.29   0.13--0.51   9,678     4,368--16,782     441,543         199,312--765,693
  Urinary tract infection                                    3,710                  18.9                        1.10   0.85--1.43    16,491        12,822--21,455        869,941         572,105--1,278,951         1,233   32.0   1.29   0.87--1.66   42,687    28,898--54,825    1,298,388       878,983--1,667,596
  Surgical site infection                                    3,601                  18.3                        1.08   0.81--1.44    16,130        12,185--21,715        518,182         293,036--858,222           66      1.7    0.09   0.03--0.20   2,829     944--6,500        57,366          19,133--131,803
  Bloodstream infection                                      2,116                  10.8                        0.69   0.48--1.00    10,294        7,241--15,097         375,050         227,552--613,624           19      0.5    0.04   0.01--0.07   1,168     193--2,389        23,692          3,908--48,442
  Gastrointestinal infection                                                                                                                                                                                                                                                                       
  *Clostridium difficile* infection                          951                    4.8                         0.32   0.21--0.51    4,786         3,105--7,721          189,526         105,154--340,978           37      1.0    0.05   0.01--0.14   1,787     424--4,755        18,118          4,296--48,206
  Other gastrointestinal infection                           792                    4.0                         0.24   0.14--0.41)   3,549         2,108--6,166          144,926         64,880--312,212            75      1.9    0.1    0.03--0.20   3,187     1,012--6,473      145,409         46,184--295,333
  Skin and soft tissue infection                             823                    4.2                         0.21   0.13--0.36    3,146         1,900--5,451          108,269         45,149--242,816            828     21.5   0.83   0.51--1.19   27,459    17,021--39,307    626,415         388,293--896,687
  Eye, ear, nose or mouth infection                          557                    2.8                         0.16   0.09--0.35    2,400         1,278--5 194          123,091         54,155--303,206            183     4.7    0.17   0.08--0.31   5,712     2,707--10,369     173,733         82,323--315,390
  Systemic infection                                         1,069                  5.4                         0.29   0.17--0.52    4,388         2,586--7,799          251,237         110,732--549,877           35      0.9    0.04   0.01--0.08   1,223     286--2,534        37,201          8,691--77,061
  Other infection                                            969                    4.9                         0.30   0.19--0.50    4,518         2,867--7,574          154,138         65,647--332,357            102     2.6    0.12   0.04--0.24   3,878     1,366--8,077      117,958         41,556--245,683
  All types of HAI, EU/EEA^a^                                19,626                 100                         NA     NA            88,204        62,697--129,630       3,779,677       2,197,869--6,492,437       3,858   100    NA     NA           133,565   78,576--200,494   4,111,544       2,425,610--6,115,682
  **All types of HAI, EU/EEA, corrected after validation**   NA                     NA                          NA     NA            **104,177**   **74,743--152,575**   **4,464,159**   **2,620,139--7,641,606**   NA      NA     NA     NA           143,565   64,736--260,655   **4,422,629**   **1,998,384--7,950,784**

cCI: cumulative 95% confidence interval (sum of country-specific lower respectively upper country interval limits); EU/EEA: European Union/European Economic Area; HAI: healthcare-associated infection; NA: not applicable; NI: not included in protocol; PPS: point prevalence survey.

^a^ After correction for non-participating countries. Cumulative sums are rounded and may differ from the sum of the individual rounded country estimates.

^b^ Other lower respiratory tract infections included bronchitis, tracheobronchitis, bronchiolitis, tracheitis, lung abcess or empyema, without evidence of pneumonia.

A total of 13,085 microorganisms were reported in 10,340 (52.7%) HAI. The 10 most frequently isolated microorganisms were *E. coli* (16.1%), *S. aureus* (11.6%), *Klebsiella* spp. (10.4%), *Enterococcus* spp. (9.7%), *P. aeruginosa* (8.0%), *C. difficile* (7.3%), coagulase-negative staphylococci (7.1%), *Candida* spp. (5.2%), *Enterobacter* spp. (4.4%) and *Proteus* spp. (3.8%).

### Antimicrobial resistance in healthcare-associated infections and correlation with EARS-Net data

AST data were available for 8,031 (88.9%) of 9,034 microorganisms included in the composite index of AMR. The index was 31.6% overall (mean of countries: 30.8%) and varied from 0% in Iceland to 68.9% in Romania. The index by country was strongly correlated with the index calculated from 2016 EARS-Net data on invasive isolates (Spearman's correlation coefficient *rho*: 0.93; p \< 0.001; R^2^: 0.86. [Figure](#f1){ref-type="fig"}) and was on average 36% higher for HAI in ACH from the PPS than in the EARS-Net data (mean of countries in EARS-Net: 20.3%). Carbapenem resistance in Enterobacteriaceae was 6.2% overall (mean of countries: 5.9%) and ranged from 0% in Estonia, Finland, Iceland, Lithuania and UK--Northern Ireland to 43.7% in Greece ([Table 4](#t4){ref-type="table"}). This indicator also correlated well with carbapenem resistance in *E. coli* and *K. pneumoniae* in EARS-Net data (Spearman's *rho*: 0.76; p \< 0.001) and was on average 45% higher in HAI in ACH from the PPS than in EARS-Net data (mean of countries in EARS-Net: 2.6%). The total number of patients acquiring an HAI with at least one resistant microorganism was estimated at 291,067 (95% cCI: 162,417--504,270) patients for the composite index of AMR and 31,696 (95% cCI: 14,611--78,205) patients for carbapenem-resistant Enterobacteriaceae.

![Correlations of composite index of antimicrobial resistance, EU/EEA countries and Serbia, 2016--2017](1800516-f1){#f1}

###### Composite index of antimicrobial resistance in bacteria from healthcare-associated infections in acute care hospitals (n = 8,413) and long-term care facilities (n = 565), 30 EU/EEA countries, Serbia and the former Yugoslav Republic of Macedonia^a^, 2016--2017

  Country                                 Acute care hospitals^a^   Long-term care facilities^a^                                                                                                                               
  --------------------------------------- ------------------------- ------------------------------ ------------- ---------------------- ----------- --------- ------------ -------------------- --------- ---------- --------- ---------
  Austria^b^                              217                       12.4                           1,759         713--3,984             124         0.8       55           8--387               16        12.5       12        0.0
  Belgium                                 495                       18.6                           8,458         4,422--14,621          318         1.3       261          104--654             45        15.6       34        0.0
  Bulgaria^b^                             53                        56.6                           8,687         3,189--23,328          30          10.0      2,014        479--8,291           NP        NA         NA        NA
  Croatia^b^                              280                       41.4                           3,823         2,491--5,808           114         5.3       300          80--1,053            6         NA         4         NA
  Cyprus^a,b^                             37                        51.4                           1,070         431--2,380             15          6.7       19           3--119               0         NA         NA        NA
  Czech Republic^a^                       627                       30.8                           16,348        9,726--25,665          393         0.8       87           30--261              NP^a^     NA         NA        NA
  Denmark^a^                              NP                        NA                             UNK           NA                     NA          NA        UNK          NA                   0         NA         0         NA
  Estonia                                 107                       13.1                           462           138--1,398             58          0.0       0            NA                   NP        NA         NA        NA
  Finland                                 188                       7.4                            298           139--619               92          0.0       0            NA                   44        6.8        36        0.0
  France^a^                               738                       21.4                           44,953        21,316--86,180         413         0.5       785          129--4,943           41        24.4       35        14.3
  Germany                                 197                       18.8                           27,228        13,378--52,651         95          2.1       1,769        420--7,444           2         NA         1         NA
  Greece^b^                               456                       61.2                           10,605        7,809--14,193          197         43.7      4,157        2,467--6,831         2         NA         1         NA
  Hungary                                 256                       37.9                           5,383         2,578--9,837           126         0.8       41           6--289               7         NA         6         NA
  Iceland                                 15                        0.0                            0             NA                     10          0.0       0            NA                   NP        NA         NA        NA
  Ireland                                 192                       25.0                           1,206         454--2,704             107         0.9       45           6--306               28        17.9       12        8.3
  Italy                                   555                       42.3                           63,930        39,969--98,909         306         16.7      11,660       6,489--20,554        93        32.3       67        5.6
  Latvia                                  47                        59.6                           804           309--2,043             19          5.3       38           4--356               NP        NA         NA        NA
  Lithuania                               108                       32.4                           1,509         680--3,224             35          0.0       0            NA                   2         .          3         NA
  Luxembourg^b^                           67                        14.9                           79            26--228                38          2.6       4            0--46                3         .          2         NA
  Malta^b^                                33                        24.2                           195           69--544                25          4.0       23           0--2,216             15        60.0       7         NA
  The Netherlands^b^                      110                       14.5                           2,755         1,201--6,052           73          2.7       167          40--688              15        26.7       13        0.0
  Norway^a^                               ND                        NA                             UNK           NA                     ND          NA        UNK          NA                   ND        NA         ND        NA
  Poland^b^                               531                       39.9                           30,356        18,445--47,719         262         6.9       2,535        976--6,569           21        42.9       13        0.0
  Portugal                                829                       38.4                           9,177         5,431--14,287          462         6.9       1,062        347--2,643           65        41.5       47        10.6
  Romania                                 164                       68.9                           13,913        7,377--25,458          80          33.8      3,475        1,726--6,923         NP        NA         NA        NA
  Slovakia                                164                       34.8                           3,061         1,543--5,848           101         2.0       247          60--1,022            8         NA         4         NA
  Slovenia                                194                       17.0                           969           397--2,087             117         1.0       3            1--17                NP        NA         NA        NA
  Spain                                   926                       26.6                           25,722        15,842--38,973         512         4.1       2,632        1,136--5,609         134       31.3       82        0.0
  Sweden                                  NP                        NA                             UNK           NA                     NA          NA        UNK          NA                   3         NA         1         NA
  UK--England                             370                       20.5                           7,634         3,950--13,560          205         1.5       316          101--986             NP        NA         NA        NA
  UK--Northern Ireland                    40                        25.0                           333           145--758               17          0.0       0            NA                   2         NA         0         NA
  UK--Scotland^a^                         ND                        NA                             UNK           NA                     ND          NA        UNK          NA                   ND        NA         ND        NA
  UK--Wales                               35                        37.1                           351           67--1,213              8           NA        0            NA                   1         NA         0         NA
  **EU/EEA^c^**                           **8,031**                 **31.6**                       **291,067**   **162,417--504,270**   **4,352**   **6.2**   **31,696**   **14,611--78,205**   **553**   **28.0**   **380**   **4.2**
  Former Yugoslav Republic of Macedonia   NP                        NA                             UNK           NA                     ND          NA        UNK          NA                   2         NA         1         NA
  Serbia                                  382                       62.0                           7,555         4,516--12,230          201         25.4      1,435        801--2,481           10        40.0       8         NA

AMR: antimicrobial resistance; CI: confidence interval; EU/EEA: European Union/European Economic Area; HAI: healthcare-associated infection; NA: not applicable; ND: no data collected in national PPS; NP: did not participate; PPS: point prevalence survey; UNK: unknown; UK: United Kingdom.

^a^Antimicrobial resistance data were not reported by Norway and UK--Scotland in the PPS in acute care hospitals and by Denmark, Norway and UK--Scotland in the PPS in long-term care facilities. Cyprus did not submit case-based HAI data for long-term care facilities. The Czech Republic only collected institutional indicators for the PPS in long-term care facilities. For France, the percentage of non-susceptible (resistant + intermediate) isolates is given instead of the percentage resistant isolates.

^b^Country data representativeness was poor in Bulgaria and the Netherlands for the PPS in acute care hospitals and poor in Austria, Croatia, Cyprus, Greece, Luxembourg, Malta and Poland for the PPS in long-term care facilities.

^c^Cumulative 95% confidence intervals for the EU/EEA. Cumulative sums are rounded and may differ from the sum of the individual rounded country estimates.

Composite index of AMR: *Staphylococcus aureus* resistant to meticillin, *Enterococcus faecium* and *Enterococcus faecalis* resistant to vancomycin, Enterobacteriaceae resistant to third-generation cephalosporins, *Pseudomonas aeruginosa* and *Acinetobacter baumannii* resistant to carbapenems. Enterobacteriaceae selected for the AMR markers: *Escherichia coli, Klebsiella* spp., *Enterobacter* spp., *Proteus* spp., *Citrobacter* spp., *Serratia* spp. and *Morganella* spp. The percentage of resistance was not calculated if less than 10 isolates were reported.

Point prevalence survey in long-term care facilities
----------------------------------------------------

### Participation

In total, 3,062 LCTF from 24 EU/EEA countries and two EU candidate countries (Serbia and the former Yugoslav Republic of Macedonia) participated in the third PPS of HAI and antimicrobial use in European LCTF in the period 2016 to 2017. Counting UK administrations separately, good or optimal representativeness of the national sample was obtained in 18 of 24 EU/EEA countries. After adjustment for over-representation, 117,138 residents from 2,221 LCTF were included for analysis. The main aggregated results were reported for 80.5% of participating LCTF, i.e. general nursing homes (n = 1,025), residential homes (n = 176) and mixed LCTF (n = 587), corresponding to 102,301 residents and 1,788 LCTF in EU/EEA countries. The characteristics of LCTF and residents by country are shown in [Table 1](#t1){ref-type="table"}.

### Prevalence of healthcare-associated infections

A total of 3,858 HAI were reported in 3,780 residents with HAI (1.02 HAI per infected resident). The prevalence of residents with at least one HAI was 3.7% (country range: 0.9--8.5%). When extrapolated to the average number of occupied LTCF beds per country, the weighted HAI prevalence in LCTF was 3.6% (95% cCI: 2.9--4.5%). Validation of the PPS in LCTF was performed for 953 residents in 17 LCTF in 10 countries. National validation teams found 1.1% (95% CI: 0.5--2.0%) false-negative residents and 19.6% (95% CI: 9.4--33.9%) false-positive residents, yielding a sensitivity of 73.7% and a specificity of 99.2% when applied on the total EU/EEA database. The country-weighted, validation-corrected HAI prevalence was 3.9% (95% cCI: 2.4--6.0%). Applying the EU/EEA prevalence to denominator data from non-participating EU/EEA countries, the total number of residents with at least one HAI on any given day in EU/EEA LCTF was estimated at 129,940 (95% cCI: 79,570--197,625) residents ([Table 5](#t5){ref-type="table"}).

###### Prevalence of healthcare-associated infections in long-term care facilities, 23 EU/EEA countries^a^, Serbia and the former Yugoslav Republic of Macedonia, 2016--2017 (n = 103,763 residents)

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Country                                   LCTF included\   Residents included in analysis   Residents with at least one HAI\    HAI from other facility^c^   HAI prevalence origin own LTCF^d^   LTCF beds\       Residents with at least one HAI on a given day, estimated                                 
                                            in analysis                                       in PPS sample (HAI prevalence)^b^                                                                    in the country                                                                                             
  ----------------------------------------- ---------------- -------------------------------- ----------------------------------- ---------------------------- ----------------------------------- ---------------- ----------------------------------------------------------- --------------- ------------- ---------------------
  Austria^e^                                12               2,065                            105                                 5.1                          2.8--8.9                            6.5              4.6                                                         72,602          3,504         1,966--6,145

  Belgium                                   79               8,206                            354                                 4.3                          3.6--5.1                            4.9              3.6                                                         146,462         5,997         5,037--7,152

  Croatia^e^                                8                1,607                            15                                  0.9                          0.4--1.9                            13.3             0.7                                                         37,249          329           159--679

  Cyprus^e^                                 11               312                              15                                  4.8                          2.7--7.8                            ND               ND                                                          3,436           157           89--255

  Denmark                                   95               3,346                            175                                 5.2                          4.5--6.1                            5.0              4.8                                                         42,668          2,120         1,808--2,481

  Finland                                   149              5,914                            208                                 3.5                          3.0--4.1                            5.1              3.2                                                         50,373          1,685         1,436--1,967

  France^f^                                 91               6,957                            206                                 3.0                          2.6--3.4                            ND               3.0                                                         687,936         19,352        16,831--22,134

  Germany                                   82               6,705                            115                                 1.7                          1.3--2.3                            13.0             1.3                                                         852,849         13,936        10,209--18,878

  Greece^e^                                 13               812                              51                                  6.3                          3.7--10.5                           3.8              5.9                                                         10,849          647           381--1,079

  Hungary                                   75               7,670                            73                                  1.0                          0.7--1.4                            4.1              0.9                                                         57,929          523           369--743

  Ireland                                   109              5,613                            276                                 4.9                          4.2--5.8                            6.0              4.5                                                         30,531          1,427         1,207--1,682

  Italy                                     196              11,417                           442                                 3.9                          3.3--4.6                            13.6             3.1                                                         186,872         6,870         5,787--8,149

  Lithuania                                 26               3,438                            32                                  0.9                          0.4--1.9                            15.6             0.6                                                         11,722          104           50--212

  Luxembourg^e^                             16               1,616                            30                                  1.9                          1.1--3.0                            0.0              1.8                                                         6,966           123           75--199

  Malta^e^                                  11               2,485                            76                                  3.1                          1.6--5.9                            12.3             2.3                                                         5,035           146           75--281

  The Netherlands^f^                        57               4,547                            160                                 3.5                          3.0--4.1                            5.0              3.2                                                         92,000          3,075         2,624--3,580

  Norway^f^                                 62               2,447                            119                                 4.9                          4.0--5.8                            2.5              4.6                                                         39,583          1,829         1,521--2,178

  Poland^e^                                 24               2,281                            90                                  3.9                          2.1--7.3                            7.6              3.5                                                         17,291          649           345--1,198

  Portugal                                  132              3,633                            214                                 5.9                          4.5--7.6                            15.9             4.3                                                         8,400           470           362--608

  Slovakia                                  59               5,091                            108                                 2.1                          1.5--3.0                            4.5              2.0                                                         27,497          554           392--778

  Spain                                     46               6,808                            579                                 8.5                          7.0--10.3                           18.9             6.2                                                         372,306         30,064        24,688--36,501

  Sweden                                    285              3,604                            57                                  1.6                          1.2--2.1                            ND               1.6                                                         93,000          1,396         1,051--1,864

  UK--Northern Ireland                      70               2,614                            97                                  3.7                          2.9--4.7                            7.1              3.4                                                         15,924          561           443--710

  UK--Scotland                              52               2,147                            125                                 5.8                          4.5--7.5                            2.4              5.3                                                         37,746          2,087         1,610--2,697

  UK--Wales                                 28               966                              58                                  6.0                          4.4--8.2                            0.0              6.0                                                         24,646          1,405         1,026--1,915

  **Participating EU/EEA countries^b,g^**   **1,788**        **102,301**                      **3,780**                           **3.6**                      **2.9--4.5**                        **8.9**          **3.1**                                                     **2,931,872**   **99,008**    **79,539--124,064**

  Former Yugoslav Republic of Macedonia     4                294                              10                                  3.4                          2.3--4.9                            0.0              2.7                                                         1,166           38            26--55

  Serbia                                    6                1,168                            37                                  3.2                          1.9--5.1                            7.3              2.8                                                         19,654          592           362--960

                                                                                                                                                                                                                                                                                                              

  EU/EEA, corrected^g,h^                    NA               NA                               NA                                  3.6                          2.9--4.5                            NA               NA                                                          3,486,999       117,754       94,599--147,553

  **EU/EEA, corrected after validation**    NA               NA                               NA                                  **3.9**                      **2.4--6.0**                        NA               NA                                                          3,486,999       **129,940**   **79,570--197,625**
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

EU/EEA: European Union/European Economic Area; HAI: healthcare-associated infection; LTCF: long-term care facility; PPS: point prevalence survey; ND: no data collected in national protocol; UK: United Kingdom.

^a^ The Czech Republic only submitted data on institutional indicators from 11 LCTF and was not included in the current analysis.

^b^ Country-weighted HAI prevalence for the EU/EEA = estimated number of residents with at least one HAI on a single day / occupied beds; occupied beds = number of LTCF beds × average occupancy of 0.95.

^c^ Percentage of HAI imported from a hospital or another LTCF; not included in France and Sweden, and unknown for Cyprus (aggregated data).

^d^ HAI prevalence for HAI with the own LTCF as origin, i.e. excluding HAI imported from other healthcare facilities and HAI with unknown origin (Supplement).

^e^ Country data representativeness was poor in Austria, Croatia, Cyprus, Greece, Luxembourg, Malta and Poland.

^f^ France, the Netherlands and Norway used a national protocol which required imputation of non-included types of HAI.

^g^ Cumulative 95% confidence intervals for the EU/EEA.

^h^ Corrected for non-participating EU/EAA countries with estimation for Bulgaria, Czech Republic, Estonia, Iceland, Latvia, Romania, Slovenia and UK--England combined.

### Types of healthcare-associated infections and isolated microorganisms

The most frequently reported types of HAI in LCTF were respiratory tract infections (33.2% overall, 3.7% pneumonia, 22.0% other lower respiratory tract infections, 7.2% common cold/pharyngitis, 0.3% influenza), urinary tract infections (32.0%) and skin infections (21.5%). The majority of the reported HAI (84.7%) were associated with the LTCF where the PPS was performed, while 7.5% and 1.4% were associated with a hospital or another LTCF, respectively. The origin was unknown for 6.4% of HAI in LCTF. Country-weighted prevalence percentages and estimated number of infections per year are given by type of HAI in [Table 3](#t3){ref-type="table"}. The total number of HAI in LCTF in the EU/EEA, after applying EU averages for non-participating EU/EEA countries and correcting for validation, was estimated at 4.4 million (95% cCI: 2.0--8.0 million). Microbiological data in LCTF were available for 742 (19.2%) HAI. The 10 most frequently isolated bacteria were *E. coli* (30.7%), *S. aureus* (12.3%), *Klebsiella* spp. (11.4%), *Proteus* spp. (10.6%), *P. aeruginosa* (7.1%), *Enterococcus* spp. (4.8%), *C. difficile* (4.4%), *Streptococcus* spp. (2.8%) *Enterobacter* spp. (2.1%) and coagulase-negative staphylococci (1.9%).

### Antimicrobial resistance in healthcare-associated infections and correlation with data from the hospital point prevalence survey

AST results were available for 553 (77.6%) of 713 microorganisms included in the composite index of AMR. The index could be calculated for 11 countries with at least 10 isolates, and was 28.0% overall, ranging from 6.8% in Finland to 60.0% in Malta ([Table 4](#t4){ref-type="table"}). The composite index of AMR correlated well between ACH and LCTF, although Malta was an outlier ([Figure](#f1){ref-type="fig"}, Spearman's *rho* excluding Malta: 0.86; p \< 0.001; R^2^ = 0.69). On average, the percentage of resistant microorganisms was similar in both settings (regression coefficient excluding Malta: 1.08). Carbapenem resistance in Enterobacteriaceae in LCTF was 4.2% overall and did not correlate significantly with the percentage in ACH ([Table 4](#t4){ref-type="table"}).

Discussion
==========

Because both the PPS in ACH and that in LCTF were performed during 2016 and 2017, this provided the first opportunity to estimate the prevalence, incidence and annual number of HAI for ACH and for LCTF in the EU/EEA for the same time period. As expected, the overall prevalence of HAI was higher in ACH than in LCTF, also after correction based on validation study results. However, when estimating the total number of HAI, both settings were shown to have similarly high numbers of HAI annually. In total, 8.9 million distinct HAI episodes were estimated to occur annually in ACH and LCTF in the EU/EEA. In ACH, where the incidence per patient could be calculated, the number of patients with at least one HAI was estimated at 3.8 (95% cCI: 3.1--4.6) million patients per year in the period 2016 to 2017.

The country-weighted HAI prevalence before validation correction in ACH of 5.5% (95% cCI: 4.5--6.7%) was similar to the HAI prevalence of 5.7% (95% cCI: 4.5--7.4%) in the ECDC PPS in ACH in the period 2011 to 2012 \[[@r3]\]. The unweighted HAI prevalence in LCTF of 3.7% before correction was only slightly higher than the prevalence of 3.4% found in the ECDC PPS in LCTF in 2013 \[[@r6]\], although imported HAI were included in the period 2016 to 2017. The final corrected country-weighted HAI prevalence estimates of 6.5% in ACH and 3.9% in LCTF were higher because they were corrected for the results of the validation studies, which made the current estimates more robust than the previous estimates. Similarly, the estimated incidence and number of HAI in ACH presented in this study were higher than the number estimated in the ECDC PPS from 2011 to 2012 \[[@r3]\] because of the correction for the results of the validation study and should therefore not be interpreted as an increase for ACH compared with the period 2011 to 2012.

The strong correlation of the composite indices of AMR in the ECDC PPS in ACH with the EARS-Net data supports the validity of AMR data collected in the PPSs. The 36% higher percentage of resistant isolates in HAI in the ECDC PPS was expected given that EARS-Net only includes data from invasive isolates, i.e. from bloodstream infections and meningitides, and that a large proportion of isolates reported to EARS-Net are from community-associated bloodstream infections, especially for MRSA and *E. coli* resistant to third-generation cephalosporins. However, the fact that the composite index of AMR in LCTF was at the same level as in ACH, at least in countries where both indicators could be calculated, is of concern. Even though the low testing frequency in LCTF is probably biased towards HAI which are non-responsive to empiric treatment, this finding emphasises the urgent need to reinforce measures to improve infection prevention and control, antimicrobial stewardship as well as microbiological laboratory support for LCTF.

Our study has several limitations. Firstly, the small number of countries and LCTF that performed validation studies in the PPS in LCTF resulted in less robust prevalence estimates for LCTF than for ACH, even though the LTCF validation results could be used at the EU/EEA level. Secondly, the conversion from prevalence to incidence using the Rhame and Sudderth formula has been shown to have several limitations in itself, especially for smaller samples \[[@r17],[@r18]\]. The estimates depend on the estimators used, as not all data can be acquired from a cross-sectional prevalence study. Nevertheless, sensitivity analyses that we performed with more recent estimator methodology (personal communication: Niklas Willrich, 24 May 2018) \[[@r15]\] yielded EU/EEA estimates which were close to those reported here, with few exceptions at individual country level. Especially considering the wide CI, this gave more weight to our estimates (Supplement). Thirdly, the estimates also strongly depended on the quality of the national denominator data of the number of beds, and, for ACH, discharges and patient days. Providing reliable national denominator data has been shown to be difficult for many countries that sometimes provided estimates rather than precise numbers, especially for LCTF. In addition, as national denominator data for specialised LCTF were only available in two countries, a specific incidence for these types of LTCF could not be estimated. In several countries, however, the number of beds for these LCTF are included in the total number of LTCF beds for the country. We only reported results for the main types of LTCF, as these types were consistently included in all countries. Fourthly, the number of residents with at least one HAI each year could not be estimated for LCTF in the EU/EEA. Longitudinal HAI incidence data would be required to produce such estimates. Fifthly, three countries preferred using their national PPS protocols for LCTF and one country for ACH, resulting in less robust estimates. Sixthly, the total number of HAI with resistant pathogens could only be estimated for ACH because of the poor availability of microbiological results in LCTF. Moreover, the annual incidence estimates of HAI with resistant pathogens in ACH are underestimated because: (i) in almost half of the HAI in ACH, a microorganism was not reported, (ii) for 11% of the reported microorganisms, AST results were not yet available on the day of the PPS and (iii) correction for countries without data and correction for validation was not performed. Despite these limitations, the estimated number of HAI with carbapenem-resistant Enterobacteriaceae using Rhame and Sudderth conversion in our study (31,696 infections, of which 27,393 were HAI with carbapenem-resistant *E. coli* or *K. pneumoniae*) was close to the number of 33,172 infections with carbapenem-resistant *E. coli* or *K. pneumoniae* recently estimated by Cassini et al. using a totally different methodology \[[@r19]\].

The main strengths of this study are its large sample size and the use of standardised protocols for data collection and validation across participating ACH and LCTF. Despite some countries providing less representative samples, these PPSs as a whole offer a representative picture of HAI in the EU/EEA, with benchmarks to help direct future action in ACH and LCTF in participating countries.

Conclusion
==========

This study reports, to our knowledge, the most accurate and robust estimates of the total number of HAI in healthcare facilities in the EU/EEA to date, and confirms that HAI, and AMR in bacteria responsible for HAI, represent a significant healthcare issue and public health challenge for the EU/EEA. Considering that previous studies have shown that HAI in ACH alone are responsible for more deaths in the EU/EEA than all other infectious diseases under surveillance at European level \[[@r1],[@r2]\], and that our study showed that there are as many HAI in LTCF as there are in ACH, more focus needs to be dedicated to the prevention of HAI and AMR, through the application of available recommendations and guidelines \[[@r20]-[@r25]\], in both ACH and LTCF.

The authors would like to thank all the participating hospitals and long-term care facilities in particular, the staff that collected, validated and entered the data during the survey and the national teams that coordinated the surveys in each participating country and that performed the validation studies.
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